Abstract
The National Institute of Occupational Safety and Health procedure No. TEB-APR-STP-0059 recommend of measuring the respirator filtration efficiency using sodium chloride aerosol with count median diameter of 75 nm ± 20 nm and geometric standard deviation ≤1.86. This study showed that this method would overestimate the respirators’ ability to protect against submicrometer particles. In this study, we converted both mobility diameter and equivalent volume diameter to aerodynamic diameter for comparison. The results showed that one unqualified KN95 respirator (with the filtration efficiency of 72%±3% for ≥300 nm sodium chloride aerosol) still passed the test with a measured overall filtration efficiency of 98%±3%, due to its larger most penetrating particle size compared to the typical N95 respirator. In addition, after three cycle H2O2 plasma vaporous sterilizations, the most penetrating particle size for the N95 grade respirators also shifted to 250 nm – 500 nm, in which size the particles carried the peak concentration of the SARS-CoV-2 in hospitals. This size shift caused the significant difference between the size specific (250 nm – 500 nm) filtration efficiency and overall filtration efficiency using the same NaCl test aerosol. For example, after three cycle H2O2 plasma vaporous sterilizations, the size specific filtration efficiency of the N95 was 55%±2%, however, the measured overall filtration efficiency was still 86%±5%. The size Specific filtration efficiency of the KN95 was 69%±2%, but, the measured overall filtration efficiency was still 90%±3%. In order to protect health care personnel adequately, we recommend increasing the test aerosol size, and measuring the size specific filtration efficiency to evaluate the N95 alternatives (e.g. KN95), and the reuse of N95 level respirators. In addition, multi-cycle sterilization with ultraviolet germicidal irradiation appears to have fewer negative effects than H2O2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was made possible by support from the Oklahoma State Department of Health to establish this testing program, by the supply chain logistics group at the University of Oklahoma Medical Center who provided the respirators and sterilization treatments, by the University of Oklahoma Health Sciences Center VPR,s office through a COVID19 Rapid Response pilot grant, and by the student volunteers that assisted with data collection.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Oklahoma institutional review board determined that this study was not human research and was exempt from informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is available.
